

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

<https://doi.org/10.17113/ftb.64.02.26.9283>

scientific note

Ethyl Acetate Extracts of Edible Mushroom Species Enhance β -Lactam Activity Against an MRSA Isolate *in vitro*

Running head: Antibiotic Modulation of Edible Mushroom Extracts

James Blee, Peter O'Hara, Thomas Smyth and Owen Kenny*

Department of Health and Nutritional Science, Atlantic Technological University, Sligo, Ireland

Received: 24 July 2025

Accepted: 16 March 2026



Copyright © 2026 Authors retain copyright and grant the FTB journal the right of first publication under CC-BY 4.0 licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in the journal

SUMMARY

Research background. The accelerated emergence of antimicrobial resistance (AMR) has led to numerous pathogens developing resistance to available antibiotics. *Staphylococcus aureus* is a leading cause of hospital-acquired infections, and the emergence of resistant strains like methicillin-resistant *Staphylococcus aureus* (MRSA) has led to greater clinical complications and higher mortality rates. As such, restoration of first-line β -lactam antibiotic activity is a viable strategy to combat AMR. The antimicrobial activity of edible mushroom extracts is well reported; however, their use as a source of antibiotic modulators is relatively unexplored, while current reports often do not adhere to drug combination guidelines. The aim of this study was to evaluate the potential of extracts derived from 10 edible mushroom species to modulate β -lactam antibiotics against MRSA with reference to the recommended guidelines.

*Corresponding author:

E-mail: owen.kenny@atu.ie

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

Experimental approach. Antimicrobial activity (minimum inhibitory concentration (MIC)) and antibiotic-modulating activity (fractional inhibitory concentration index (FICI)) were assessed using the broth microdilution method. The cell viability assay was used to assess cell membrane integrity following treatment to offer insight into potential mechanisms of action.

Results and conclusions. Both antimicrobial and antibiotic modulatory activity solely resided in ethyl acetate extracts. *Hericium erinaceus* extract demonstrated the strongest antimicrobial activity against *S. aureus* (MIC=0.8 mg/mL), while *Agaricus bisporus* extract exhibited the strongest antibiotic-modulating properties, exhibiting a x25-fold reduction in ampicillin, amoxicillin and penicillin MIC against an MRSA isolate (FICI=0.29), indicating synergism. The mechanism of action indicates reduced cell membrane integrity, which may increase intracellular antibiotic concentration.

Novelty and scientific contribution. These results indicate the potential utilisation of ethyl acetate extracts derived from edible mushrooms as a source of antibiotic-modulating compounds, namely *A. bisporus*. To our knowledge, this is the first study to evaluate the antibiotic-modulating effects of *H. erinaceus*, *Hypsizygus tessulatus* and *Pholiota adiposa*. This study also highlights the necessity to adhere to FICI guidelines when evaluating the antibiotic-modulating potential of edible mushroom extracts.

Keywords: antibiotic modulation; edible mushrooms; MRSA; beta-lactams; *Agaricus bisporus*; antimicrobial resistance

INTRODUCTION

The accelerated emergence of antimicrobial resistance (AMR) has led to numerous pathogens developing resistance to one or more available antibiotics [1]. AMR is further complicated by a limited antibiotic pipeline, suggesting that extending the lifespan of currently available antibiotics is a necessary approach. *Staphylococcus aureus* is the leading cause of numerous hospital-acquired (HA) and community-acquired (CA) infections, including impetigo, endocarditis and bloodstream infections [2]. The annual incidence rate of *S. aureus* bloodstream infections is estimated at approximately 26.1 per 100,000 persons [3], with a typical mortality rate of 10–30 % [4]. Resistance to penicillin has been reported in over 90 % of *S. aureus* isolates [5], while methicillin-resistant *Staphylococcus aureus* (MRSA) is estimated to comprise 13–74 % of all *S. aureus* infections [6]. The

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

emergence of MRSA strains and the need for new antibiotic development have been noted by the World Health Organisation, classifying MRSA as a 'High Priority Pathogen' due to its exhibited resistance to numerous antibiotics [7]. Typically, β -lactam antibiotics are the primary treatment options for methicillin-sensitive *Staphylococcus aureus* (MSSA) infections, which demonstrate no resistance. β -lactam resistance complicates drug administration, which is indicative of the higher mortality rates associated with MRSA bacteraemia infections when compared to MSSA infections [8]. The widespread resistance to β -lactam antibiotics, coupled with a limited antibiotic pipeline, requires an alternative therapeutic approach.

One such therapeutic option is the reutilisation of the β -lactam antibiotics *via* their use with antibiotic modulators. Antibiotic modulators are compounds capable of overcoming resistance mechanisms expressed by pathogens, consequently increasing antibiotic efficacy by lowering its minimum inhibitory concentration (MIC), thus having the potential to extend the lifespan of an antibiotic [9]. *S. aureus* expresses two predominant resistance mechanisms to β -lactam antibiotics: enzymatic hydrolysis and alteration of the β -lactam substrate, penicillin-binding protein 2 (PBP2). In resistant isolates, the *mecA* gene encodes for PBP2a, which exhibits reduced affinity to β -lactam antibiotics [10]. Clavulanic acid is a notable example of a natural product-derived antibiotic modulator, capable of serving as a competitive and irreversible inhibitor of serine β -lactamases, rendering the serine β -lactamase as ineffective [11]. The combination of clavulanic acid as a modulator with amoxicillin gave rise to Augmentin, which expanded potential treatment options due to overcoming resistance mechanisms.

Initially derived from fungi, the β -lactams are one of the most important antibiotic classes in modern medicine. As such, there has been increased research interest in exploring edible mushrooms as a source of potential antimicrobial agents. A variety of edible mushroom species, such as the *Pleurotus* spp., have previously demonstrated activity against both Gram-positive (*Bacillus subtilis* and *Streptococcus faecalis*) and Gram-negative (*Escherichia coli* and *Pseudomonas aeruginosa*) bacteria by zone-of-inhibition (disc diffusion) [12]. However, to date, there are minimal studies reporting on the antibiotic-modulating properties of edible mushroom extracts. Further, the methods used to conduct and classify synergism within the few studies conducted often do not adhere to the recommended classifications [13], prompting incomparable results. For example, synergism was previously reported following a 4-fold reduction in meropenem minimum inhibitory concentration (MIC) using ethanol extracts (60 % V/V) derived from *P. ostreatus* against *E. coli* and *Klebsiella pneumonia* [14]. However, sub-inhibitory concentrations of extracts were not used, while the parameters and

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

calculation for defining synergism based on the Fractional Inhibitory Concentration Index ($FICI \leq 1$) are different from the recommended classification [13].

Despite evidence supporting the antimicrobial properties of edible mushroom extracts, the reported MICs are often too high to be considered as independent antimicrobial agents. To date, there are minimal studies reporting on the β -lactam-modulating potential of edible mushroom extracts against MRSA. Effective β -lactam modulation against MRSA may aid in inhibiting or counteracting MRSA resistance mechanisms while extending the lifespan of current β -lactam antibiotics.

Therefore, this study aims to evaluate the antibiotic-modulating potential of extracts derived from ten edible mushroom species against a clinical MRSA isolate.

MATERIALS AND METHODS

Chemicals and reagents

Organic solvents (hexane, methanol, dimethyl sulfoxide (DMSO), acetone, and ethyl acetate) were purchased from Lennox laboratory supplies (Dublin, Ireland). The β -lactam antibiotics (penicillin, oxacillin, ampicillin, and amoxicillin), nitrocefin discs, Mueller-Hinton broth and agar, propidium iodide (PI), 4',6-diamidino-2-phenylindole, (DAPI) and iodinitrotetrazolium chloride (INT) were purchased from Sigma Aldrich (Dublin, Ireland).

Sample preparation

Commercially available mushroom species were sourced and purchased from Garryhinch Wood Exotic Mushrooms, Co. Offaly, Ireland in November 2021. A mass of 1 kg of fresh mass mushrooms *Agaricus bisporus* (portobello), *Grifola frondosa* (maitake), *Hericium erinaceus* (lions mane), *Hypsizygus tessulatus* (white beech), *Lentinula edodes* (shiitake), *Pholiota adiposa* (chestnut), *Pholiota microspora* (forest nameko), *Pleurotus citrinopileatus* (golden oyster), *Pleurotus eryngii* (king oyster) and *Pleurotus ostreatus* (oyster) was freeze dried (Cuddon Freeze dry FD 80) at Teagasc Ashtown Food Research Centre, Dublin, Ireland and then blended into a fine powder (Waring Laboratory Blender). Samples were vacuum packed and stored at $-20\text{ }^{\circ}\text{C}$ until further use.

Sample extraction

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

Each freeze-dried mushroom powder (20 g) was exhaustively extracted (1:10) using a sequence of solvents of increasing polarity (hexane<methanol<water). Samples were extracted with each solvent, under agitation (150 rpm) and at room temperature, for two consecutive two-hour periods, followed by one sixteen-hour extraction. Extracts were pooled according to their respective solvent and subsequently dried using a rotary evaporator (Buchi Rotavapor R-3000, Switzerland) at 40°C, while water extracts were freeze dried (CHRIST – alpha 1-2 LD plus) and transferred to amber vials. Dried methanol extracts were reconstituted in water and then subjected to three successive rounds of liquid-liquid partitioning using 250 mL of ethyl acetate in each case. The organic solvent and water were removed as previously described. All extracts were stored at –20 °C until further use.

Bacterial strains and culture conditions

Staphylococcus aureus (ATCC 25923) was purchased from the American Type Culture Collection (ATCC). A hospital-acquired (HA) MRSA isolate was donated by Sligo University Hospital (SUH), Sligo, Ireland. All strains were stored on ceramic beads in glycerol at –80 °C. Prior to use, beads were streaked onto fresh nutrient agar plates and grown for 24 h at 37 °C. Three colonies of similar morphology were inoculated into 15 mL of Mueller-Hinton Broth and incubated for 16 h at 37 °C. The inoculum was adjusted to a final testing concentration of $5 \cdot 10^5$ CFU/mL, prior to testing. The MRSA isolate was positively typed for the *mecA* gene by SUH. MRSA tested positive, while *S. aureus* tested negative for β -lactamase production, following nitrocefin application as according to the manufacturer's guidelines (MERCK 49862).

Antimicrobial activity

The broth microdilution method was used to determine the antimicrobial activity of extracts, as described previously by Smyth *et al.* [15]. Stock solutions (8 mg/mL) of each sample extract were prepared by initially solubilising in sterile deionised water (8 % DMSO V/V). Extracts were sonicated (Elma S180 sonicator (37 kHz), Elma Ultrasonic, Germany) for 10 min and centrifuged at 4,000 rpm for 5 min using a Sorvall ST4R plus centrifuge.

Using a 96-well microtiter plate, the following controls were added in triplicate to lane one: 100 μ L of Mueller-Hinton Broth (blank control), 100 μ L of ampicillin (0.5 mg/mL, positive control), 100 μ L of bacteria culture and a 4 % (V/V) aqueous DMSO solution (final concentration for lane 1, negative control). In the remaining wells, a 2-fold serial dilution of each extract was performed in triplicate

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

across corresponding rows using Mueller-Hinton broth, resulting in a final extract concentration of 4 mg/mL. A volume of 100 μ L of bacterial culture ($5 \cdot 10^5$ CFU/mL) was added to all corresponding wells, excluding the blank control. Plates were tested in triplicate and were incubated at 37 °C for 18 h. Following incubation, 40 μ L of iodinitrotetrazolium dye (INT; 0.2 mg/mL) was added to each well to assess cell viability, where viable bacterial cells are responsible for the witnessed colour change from clear to red. The wells where no colour change was observed after incubation were determined as the MIC using biological replicates ($N=3$).

Antibiotic modulation

Extracts were evaluated for their ability to modulate four β -lactam antibiotics (ampicillin, amoxicillin, oxacillin and penicillin) against an MRSA isolate using the Fractional Inhibitory Concentration Index (FICI), as described previously by Embaby *et al.* [16]. Extracts were diluted to one quarter their respective MIC and added to subtherapeutic concentrations of antibiotic in triplicate, where they were then incubated with an inoculum of $5 \cdot 10^5$ CFU/mL at 37 °C for 18 h. Equivalent extract concentrations of DMSO (final concentration 2 % V/V) were added to the negative controls containing subtherapeutic concentrations of antibiotic. Cell viability was assessed as previously described using biological replicates ($N=3$). Antibiotic modulation was classified as synergistic (<0.5), additive ($0.5-1$), indifferent ($>1-4$), and antagonistic (>4) according to the Fractional Inhibitory Concentration Index (EQ. 1) [13].

$$FICI = \frac{MIC_{Antibiotic\ combination}}{MIC_{Antibiotic\ alone}} + \frac{MIC_{Natural\ product\ combination}}{MIC_{natural\ product\ alone}} / 1/$$

Cell viability assay

The cell viability assay was used to determine cell membrane leakage, as previously described Khamrai *et al.* [17] with minor modifications. A single MRSA colony was inoculated in Mueller-Hinton broth and incubated at 37 °C until mid-logarithmic stage absorbance (A) ($A_{600\text{ nm}}=0.5$) was reached. Next, 800 μ L of culture was added to all Eppendorf tubes. The remaining 200 μ L was comprised of the antibiotic/ extract concentration, while a 1 % V/V DMSO solution was added to the negative control (0.1 % final concentration for both extract and control). Samples were incubated for 1 h at 37 °C under agitation at 150 rpm. Following incubation, samples were centrifuged at 10,000 rpm for 8 min, where the supernatant was discarded and the pellet resuspended in 800 μ L of Ringers solution. Then, 100 μ L of 4',6-diamidino-2-phenylindole (DAPI) solution (0.1 mg/mL) and 100 μ L of propidium iodide (PI)

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

(0.1 mg/mL) were added and incubated in the dark for 30 min at 37 °C under agitation (150 rpm). Following incubation, 10 µL of sample was analysed using a Canon EOS 1300D camera attached to Nikon Eclipse 80i for fluorescent microscopy. EOS utility software was used for capturing images (400× magnification) (ISO 100) with ND4 filter applied to remove background fluorescence. Daptomycin was used as a positive control. All samples and controls were tested as biological triplicates ($N=3$).

Total phenolic content

The total phenolic content of all crude extracts was evaluated ($N=3$) as previously described Kenny *et al.* [18]. Briefly, 100 µL of extract solubilised in methanol was added to a microcentrifuge tube, followed by 100 µL of methanol, 100 µL of Folin-Ciocalteu (2N) reagent and 700 µL of sodium carbonate (20 % *m/V*). A volume of 100 µL of methanol was used in place of the extract for the blank control. Each microcentrifuge tube was vortexed and incubated in the dark, at room temperature, for 20 min. Following, samples were centrifuged at 13,000 rpm for 3 min and the absorbance was measured at 735 nm using a spectrophotometer (Jenway 6300). A gallic acid calibration curve (0.01–0.2 mg/mL) was used to express results as gallic acid equivalents (mg GAE/mg DME) following linear regression.

RESULTS AND DISCUSSION

From the forty extracts screened for their antimicrobial activity, only the ethyl acetate extracts from seven species (*A. bisporus*, *H. erinaceus*, *H. tessulatus*, *P. adiposa*, *P. citrinopileatus*, *P. eryngii* and *P. microspora*) demonstrated antimicrobial activity (MIC=0.8–4 mg/mL) against both *S. aureus* and an MRSA isolate (Table 1). No antimicrobial activity was observed in any extracts from *G. frondosa*, *L. edodes* or *P. ostreatus*, respectively. The strongest antimicrobial activity was present in *H. erinaceus* ethyl acetate extract against *S. aureus* (0.8 mg/mL). Overall, the tested crude edible mushroom extracts exhibited weak antimicrobial activity. However, extracts demonstrating weak antimicrobial activity (4 mg/mL) displayed the strongest antibiotic modulation against an MRSA isolate, suggesting their potential alternative use.

Of all tested extracts, five ethyl acetate extracts derived from *A. bisporus*, *H. erinaceus*, *H. tessulatus*, *P. adiposa* and *P. eryngii* demonstrated antibiotic modulation when combined with ampicillin, amoxicillin and penicillin against a HA-MRSA isolate (Table 2). In contrast, no antibiotic

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

modulation was observed with oxacillin, indicating that no tested extract was capable of counteracting the predominant resistance mechanism associated with oxacillin resistance, namely the low binding affinity of PBP2a.

The observed FIC index range (0.29–0.53) demonstrated by active extracts in conjunction with the ampicillin, amoxicillin and penicillin antibiotics indicates both synergistic and additive properties of tested edible mushroom extracts, while the remaining extracts demonstrated no modulating activity, resulting in indifference with respect to the FIC range ($>1-4$). *A. bisporus* exhibited the most consistent and strongest antibiotic modulatory activity, causing a 25 fold-reduction in ampicillin, amoxicillin and penicillin MIC.

Hericium erinaceus

In this study, the ethyl acetate extract exhibited the overall strongest antimicrobial activity against *S. aureus* (MIC=0.8 mg/mL). The antimicrobial activity of an *H. erinaceus* ethanol extract against *S. aureus* has been previously reported (MIC=2.5 mg/mL) [19], with the authors attributing the activity to the total phenolic content present. In the present study, the *H. erinaceus* ethyl acetate extract demonstrated an antimicrobial effect against MRSA (MIC=4 mg/mL) and a total phenolic value of 0.03112 mg GAE/mg DME, potentially suggesting that other compounds may be responsible for the outlined activity.

Despite the suggested use of *H. erinaceus* as an antibiotic modulator [20], its modulating-potential remains unknown. In this study, *H. erinaceus* demonstrated synergism (FICI \leq 0.5) with amoxicillin, ampicillin and penicillin against an MRSA isolate, with a maximum 12.5-fold MIC reduction (FICI=0.33) in combination with ampicillin. These results indicate that *H. erinaceus* may serve as a novel source of antibiotic-modulating compounds.

Hypsizygus tessulatus

In the present study, the ethyl acetate extract of *Hypsizygus tessulatus* demonstrated antimicrobial activity against both *S. aureus* and MRSA (MIC=4 mg/mL). Previous studies have reported weak antimicrobial activity (44 % inhibition) of water extracts derived from of *H. tessulatus* stalks (1.2 mg/mL) [21].

In addition to the outlined antimicrobial activity, *H. tessulatus* demonstrated synergism (FICI \leq 0.5) with ampicillin (FICI=0.37), amoxicillin (FICI=0.41) and penicillin (FICI=0.49), resulting in

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

8.3, 6.3 and 4.2-fold MIC reductions, respectively. To our knowledge, this is the first study to report on the antibiotic-modulating effects of *H. tessulatus*, highlighting it as a potential novel source of antibiotic-modulating compounds.

Pleurotus spp.

The ethyl acetate extracts of *Pleurotus citrinopileatus* were active against MRSA and *S. aureus* (MIC=1 mg/mL). Previous reports on *P. citrinopileatus* crude ethyl acetate extract indicate an antimicrobial effect against *S. aureus* (MIC=2.5 mg/mL) [22]. The lipid metabolite glucosylceramide was suggested to be responsible for the outlined activity.

In the current study, despite showing no antimicrobial activity, *P. eryngii* ethyl acetate extract (1 mg/mL) reduced ampicillin MIC x3.6-fold (FICI=0.53) against MRSA, indicating additive properties (FICI=0.5–1). A previous study [23] reported synergism (FICI=<0.5) between a *P. eryngii* water extract (400 mg/mL) combined with ampicillin against a *S. aureus* isolate (FICI=0.19).

In this study, *P. ostreatus* extracts exhibited no antimicrobial or antibiotic modulating properties. A previous study reported the antimicrobial activity of *P. ostreatus* mycelial extract (methanol: glycerol: water, 1:1:1 V/V) against *S. aureus* by zone-of-inhibition (disc diffusion) of (29.0±0.31) mm at an unreported concentration [24]. However, it did not demonstrate antibiotic modulation with norfloxacin against *B. subtilis*. Aqueous ethanol extracts (60 % V/V) derived from *P. ostreatus* were evaluated for meropenem-modulating properties (25 mg/mL) against extended-spectrum β -lactamase-producing *E. coli* and *K. pneumoniae* isolates [14]. A 4-fold reduction in meropenem MIC was reported; however, the extracts were not tested at subinhibitory concentrations, and synergism was defined using a FICI threshold of ≤ 1 . In addition, the isolates exhibited no baseline resistance to meropenem prior to modulation. Similarly, a methanol extract (80 % V/V) derived from *Fistulina hepatica* (20 mg/mL) demonstrated synergistic activity (FICI=0.3) in combination with penicillin and ampicillin against MRSA [25]. As in the previous study [14], subinhibitory concentrations of the mushroom extracts were not evaluated, reflecting differences in experimental design and criteria used to define synergism.

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

Pholiota spp.

The antimicrobial and antibiotic modulating activity of species derived from the *Pholiota* family remain scarce. Thus, to the best of our knowledge, this is the first report on the antimicrobial (MIC=1 mg/mL) activity of *Pholiota microspora*.

In the present study, *P. adiposa* demonstrated inhibitory properties against both MRSA and *S. aureus* (MIC=4 mg/mL), while also exhibiting a 25-fold reduction in ampicillin MIC against MRSA (FICI=0.29), indicating synergism (FICI \leq 0.5). Previous studies evaluating the antimicrobial activity of ethanolic extracts derived from *P. adiposa* reported greater activity against MRSA (MIC=0.1 mg/mL) and *S. aureus* (MIC=0.2 mg/mL) [26]. In that study, MIC values were determined using an agar dilution method, although the inoculum size was not specified. The relatively low abundance of phenolics in *P. adiposa* ethyl acetate extract ((0.02561 \pm 0.00018) mg GAE/mg DME) in the present study suggests that non-phenolic compounds may be responsible for the reported activity.

Agaricus bisporus

In this study, *A. bisporus* ethyl acetate extract demonstrated inhibition against both *S. aureus* and MRSA (MIC=4 mg/mL). *A. bisporus* methanolic (MIC=0.6 mg/mL) and ethanolic (MIC=0.03 mg/mL) extracts have previously demonstrated antimicrobial activity against *S. aureus* [27]. Notably, the bacterial inoculum tested was 1 \cdot 10⁴ CFU/mL, which is lower than that in this study (5 \cdot 10⁵ CFU/mL) and might explain the variance. The *A. bisporus* ethyl acetate extract contained (0.03322 \pm 0.00044) mg GAE/mg DME, which may indicate that phenolics are not responsible for the observed activity.

A. bisporus ethyl acetate extract was the most effective antibiotic modulating extract, lowering the MIC of penicillin, ampicillin, and amoxicillin to 0.01 mg/mL, a 25-fold reduction (FICI=0.29), indicating antibiotic synergism. A previous study demonstrated synergistic effects between *A. bisporus* ethanol and acetone extracts (25 mg/mL) and the anti-staphylococcal drug, AFN-1252 (0.0005 mg/mL), with the authors noting the potential application of *A. bisporus* as an antibiotic modulator [28]. It was suggested that unsaturated fatty acids, in particular linoleic acid, were responsible for the outlined activity, most likely by disrupting the cell membrane and cell wall of the MRSA isolate. Synergism was inferred without the calculation of the FICI value, as the MIC of the *A. bisporus* extract was not determined.

In this study, the ethyl acetate extract of *A. bisporus* has demonstrated increased cell membrane permeability through the cell viability assay (Fig. 1). When subtherapeutic concentrations

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

of *A. bisporus* and ampicillin are tested individually, there is minimal effect on cell membrane damage. However, when both *A. bisporus* and ampicillin are used as a combination therapy, there is a notable increase in cell membrane leakage. Similarly, an ethanol extract derived from *A. bisporus* has previously shown cell membrane leakage against *S. aureus* (MIC=9.54 mg/mL) when used as an antimicrobial agent [29]. This finding may illustrate the mechanism of action responsible for *A. bisporus* ability to modulate β -lactam antibiotics. It is suggestive that decreasing cell membrane integrity facilitates the localised concentration of antibiotic within the penicillin-binding protein domains, while simultaneously accelerating osmotic imbalance and subsequent cell lysis. However, no modulation was observed with oxacillin. Oxacillin resistance in MRSA is mediated by low β -lactam affinity for PBP2a while being resistant to the effects of β -lactamase, resulting in maximal activity to native PBPs. Consequently, an increase in membrane permeability or a reduction in β -lactamase activity would not be sufficient to enhance oxacillin activity, because the predominant resistance mechanism, PBP2a, remains unaffected.

A. bisporus is one of the most cultivated edible mushrooms globally, while it is estimated that 5–20 % of *A. bisporus* production generated is wasted due to physical abnormalities [30]. While the repurposing of *A. bisporus* waste may serve as a sustainable source of effective antibiotic modulators, the approach has certain limitations for use in the food and biotechnology sectors. The active extract is obtained in low yields (0.48 % from dry mass; Table 3), which may provide difficulty for further purification and bioactivity-guided fractionation testing. In addition, the above results are obtained from a single MRSA isolate, which may not reflect the genetic and phenotypic diversity of MRSA strains, thereby limiting the broader applicability of the results. These factors indicate that further optimisation and testing against additional clinical isolates are needed before *A. bisporus* waste-derived antibiotic modulators can be translated into industrial or clinical applications.

CONCLUSIONS

Of the minimal studies reporting on the antibiotic-modulating properties of edible mushroom species, there is considerable variation in the methods used for evaluating and classifying synergism, which further limits result comparison. This study has successfully outlined the antibiotic-modulating potential of ten edible mushroom species when combined with β -lactam antibiotics against a single MRSA isolate, with reference to recommended FICI classifications. Furthermore, this is the first study to assess the antibiotic modulating properties of *H. erinaceus*, *H. tessulatus* and *P. adiposa*.

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

The results presented in this study demonstrate the potential application of extracts derived from edible mushrooms as a source of antibiotic-modulating compounds. In particular, the antibiotic-modulating effects of *A. bisporus* has been demonstrated. It is hypothesised that *A. bisporus* ethyl acetate extract interferes with cell membrane integrity, leading to increased β -lactam uptake. The results of *A. bisporus* ethyl acetate extract offer a potential use for β -lactam modulation against MRSA. Further research into the identification of the responsible analyte(s) is warranted.

ACKNOWLEDGEMENTS

The authors would also like to thank Sligo University Hospital, Ireland for supplying the clinical MRSA isolate. Additionally, the authors would like to thank Garryhinch Wood Exotic Mushrooms (Ireland) for providing the mushroom biomass used in this study.

FUNDING

This study was fully funded through the President's Bursary Scheme (Grant Number: PPRES080) at Atlantic Technological University, Sligo, Ireland.

CONFLICT OF INTEREST

No conflict of interest declared.

SUPPLEMENTARY MATERIAL

All supplementary materials are available at: www.ftb.com.hr.

AUTHOR' CONTRIBUTIONS

J. Blee was responsible for investigation, methodology, visualisation, writing - original draft, writing - review & editing. P. O'Hara was responsible for investigation, methodology, visualisation, writing - review & editing. T. Smyth was responsible for conceptualization, funding acquisition, methodology, resources, supervision, writing - review & editing. O. Kenny was responsible for conceptualization, funding acquisition, methodology, resources, supervision, writing - review & editing.

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

ORCID ID

J. Blee <https://orcid.org/0000-0003-2709-1865>

P. O'Hara <https://orcid.org/0009-0002-9661-1895>

T. Smyth <https://orcid.org/0000-0003-2913-3782>

O. Kenny <https://orcid.org/0000-0002-1206-535X>

REFERENCES

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, *et al.* Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis.* 2009;48(1):1-12.
<https://doi.org/10.1086/595011>
2. Pollitt E, Szkuta P, Burns N, Foster S. *Staphylococcus aureus* infection dynamics. *PLoS Pathog.* 2018;14(6):1-26. PubMed PMID: 130152208.
<https://doi.org/10.1371/journal.ppat.1007112>
3. Laupland KB, Lyytikäinen O, Søgaard M, Kennedy KJ, Knudsen JD, Ostergaard C, *et al.* The changing epidemiology of *Staphylococcus aureus* bloodstream infection: a multinational population-based surveillance study. *Clin Microbiol Infect.* 2013;19(5):465-71. PubMed PMID: 86882058.
<https://doi.org/10.1111/j.1469-0691.2012.03903.x>
4. Bai AD, Lo CKL, Komorowski AS, Suresh M, Guo K, Garg A, *et al.* *Staphylococcus aureus* bacteraemia mortality: a systematic review and meta-analysis. *Clin Microbiol Infect.* 2022 08/01/August 2022;28(8):1076-84. PubMed PMID: S1198743X22001549.
<https://doi.org/10.1016/j.cmi.2022.03.015>
5. Livermore DM. Antibiotic resistance in staphylococci. *Int J Antimicrob Agents.* 2000 01/01/January 2000;16(Supplement 1):3-10. PubMed PMID: S0924857900002995.
[https://doi.org/10.1016/S0924-8579\(00\)00299-5](https://doi.org/10.1016/S0924-8579(00)00299-5)
6. Köck R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, *et al.* Methicillin-resistant *Staphylococcus aureus* (MRSA): burden of disease and control challenges in Europe. *Euro Surveill.* 2010;15(41).
<https://doi.org/10.2807/ese.15.41.19688-en>
7. WHO. Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024.
8. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* bacteremia: a meta-analysis. *Clin Infect Dis.* 2003;36(1):53-9.
<https://doi.org/10.1086/345476>

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

9. Laws M, Shaaban A, Rahman KM. Antibiotic resistance breakers: current approaches and future directions. *FEMS Microbiol Rev.* 2019;43(5):490-516. PubMed PMID: 138591669.

<https://doi.org/10.1093/femsre/fuz014>

10. Fishovitz J, Hermoso JA, Chang M, Mobashery S. Penicillin-binding protein 2a of methicillin-resistant *Staphylococcus aureus*. *IUBMB Life.* 2014;66(8):572-7.

<https://doi.org/10.1002/iub.1289>

11. Lang PA, de Munnik M, Oluwole AO, Claridge TDW, Robinson CV, Brem J, *et al.* How clavulanic acid inhibits serine β -Lactamases. *CheBioChem.* 2024;25(22):e202400280. PubMed PMID: 39052765.

<https://doi.org/10.1002/cbic.202400280>

12. Gashaw G, Fassil A, Redi F. Evaluation of the antibacterial activity of *Pleurotus* spp. cultivated on different agricultural wastes in Chiro, Ethiopia. *Int J Microbiol.* 2020:1-9. PubMed PMID: 145340248.

<https://doi.org/10.1155/2020/9312489>

13. Odds FC. Synergy, antagonism, and what the checkerboard puts between them. *J Antimicrob Chemother.* 2003;52(1):1. PubMed PMID: 12805255.

<https://doi.org/10.1093/jac/dkg301>

14. Chatterjee D, Halder D, Das S. Synergistic activity of the antibiotic meropenem in combination with edible mushroom extracts against multidrug resistant bacteria. *Br J Pharm Res.* 2016;10(6):1-7.

<https://doi.org/10.9734/BJPR/2016/24834>

15. Smyth T, Ramachandran VN, Smyth WF. A study of the antimicrobial activity of selected naturally occurring and synthetic coumarins. *Int J Antimicrob Agents.* 2009 05/01/May 2009;33(5):421-6. PubMed PMID: S0924857908005384.

<https://doi.org/10.1016/j.ijantimicag.2008.10.022>

16. Embaby MA, El-Raey MA, Zaineldain M, Almaghrabi O, Marrez DA. Synergistic effect and efflux pump inhibitory activity of *Ficus nitida* phenolic extract with tetracycline against some pathogenic bacteria. *Toxin Rev.* 2021 12//;40(4):1187-97.

<https://doi.org/10.1080/15569543.2019.1659370>

17. Khamrai M, Banerjee SL, Paul S, Samanta S, Kundu PP. Curcumin entrapped gelatin/ionically modified bacterial cellulose-based self-healable hydrogel film: An eco-friendly sustainable synthesis method of wound healing patch. *Int J Biol Macromol.* 2019;122:940-53.

<https://doi.org/10.1016/j.ijbiomac.2018.10.196>

18. Kenny O, Smyth TJ, Hewage CM, Brunton NP. Antioxidant properties and quantitative UPLC-MS analysis of phenolic compounds from extracts of fenugreek (*Trigonella foenum-graecum*) seeds and bitter melon (*Momordica charantia*) fruit. *Food Chem.* 2013;141(4):4295-302.

<https://doi.org/10.1016/j.foodchem.2013.07.016>

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

19. Kim M-U, Lee E-H, Jung H-Y, Lee S-Y, Cho Y-J. Inhibitory activity against biological activities and antimicrobial activity against pathogenic bacteria of extracts from *Hericium erinaceus*. J Appl Biol Chem. 2019;62(2):173-9.
<https://doi.org/10.3839/jabc.2019.024>

20. Suleiman WB, Shehata RM, Younis AM. In vitro assessment of multipotential therapeutic importance of *Hericium erinaceus* mushroom extracts using different solvents. Bioresour Bioprocess. 2022;9(1):1-13.
<https://doi.org/10.1186/s40643-022-00592-6>

21. Shah SR, Ukaegbu CI, Hamid HA, Alara OR. Evaluation of antioxidant and antibacterial activities of the stems of *Flammulina velutipes* and *Hypsizygus tessellatus* (white and brown var.) extracted with different solvents. J Food Meas Charact. 2018;12:1947-61.
<https://doi.org/10.1007/s11694-018-9810-8>

22. Chomcheon P, Kheawkum B, Sriwiset P, Dulsamphan S, Dulsamphan C. Antibacterial activity of crude extracts from edible mushrooms *Pleurotus citrinopileatus* and *Tricholoma crassum* Berk. Thai J Pharm Sci. 2013;37:107-11.
<https://doi.org/10.56808/3027-7922.3324>

23. Tinrat S. Antimicrobial activities and synergistic effects of the combination of some edible mushroom extracts with antibiotics against pathogenic strains. Int J Pharm Sci Rev Res. 2015;35(2):253-62.

24. El-Rahman T, Abd MA, Naguib RM, Sayed SM, Saleh AM, Alaa AM, *et al.* Combination antimicrobial efficacy between the mushroom (*Pleurotus ostreatus*) and some commercial antibiotics. IJAREAS. 2016;5(7):56-72.

25. Alves MJ, Ferreira ICFR, Lourenço I, Castro A, Pereira L, Martins A, *et al.* Wild mushroom extracts potentiate the action of standard antibiotics against multiresistant bacteria. J Appl Microbiol. 2014;116(1):32-8.
<https://doi.org/10.1111/jam.12348>

26. Islek C, Saridogan BGO, Sevindik M, Akata I. Biological activities and heavy metal contents of some *Pholiota* species. Fresenius Environ Bull. 2021;30(6):6109-14.

27. Stojković D, Reis FS, Glamočlija J, Ćirić A, Barros L, Van Griensven LJLD, *et al.* Cultivated strains of *Agaricus bisporus* and *A. brasiliensis*: chemical characterization and evaluation of antioxidant and antimicrobial properties for the final healthy product–natural preservatives in yoghurt. Food Funct. 2014;5(7):1602-12.
<https://doi.org/10.1039/C4FO00054D>

28. Milica J, Vincent L, Uroš G, Jamila A-M, Maja Krstić R, Aleksandra R, *et al.* Antibacterial activities of *Agaricus bisporus* extracts and their synergistic effects with the antistaphylococcal drug AFN-1252. Foods. 2024 01/01;13(11):1715.
<https://doi.org/10.3390/foods13111715>

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

29. Erdođan Eliuz EA. Antibacterial activity and antibacterial mechanism of ethanol extracts of *Lentinula edodes* (shiitake) and *Agaricus bisporus* (button mushroom). *Int J Environ Health Res.* 2022;32(8):1828-41.

<https://doi.org/10.1080/09603123.2021.1919292>

30. Ramos M, Burgos N, Barnard A, Evans G, Preece J, Graz M, *et al.* *Agaricus bisporus* and its by-products as a source of valuable extracts and bioactive compounds. *Food Chem.* 2019;292:176-87.

<https://doi.org/10.1016/j.foodchem.2019.04.035>

Table 1. The antimicrobial activity of ethyl acetate extracts derived from edible mushrooms against two bacterial isolates

Species	<i>S. aureus</i> ATCC 25923 (mg/mL)	HA-MRSA (mg/mL)
<i>A. bisporus</i>	4	4
<i>G. frondosa</i>	>4	>4
<i>H. erinaceus</i>	0.8	4
<i>H. tessulatus</i>	4	4
<i>L. edodes</i>	>4	>4
<i>P. adiposa</i>	4	4
<i>P. citrinopileatus</i>	1	1
<i>P. eryngii</i>	4	4
<i>P. microspora</i>	1	1
<i>P. ostreatus</i>	>4	>4

>4 indicates no activity at the maximum concentration tested (4 mg/mL). Values are means of replicate assays (N=3)

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

Table 2. The antibiotic modulating properties of edible mushroom species ethyl acetate extracts against a HA-MRSA isolate

Species	MIC (mg /mL)			Fold-reduction	FIC Index Score
	Extract (¼)	Antibiotic	Combination		
<u>Ampicillin</u>					
<i>A. bisporus</i>	1.0	0.25	0.01	25.0	0.29 ^S
<i>G. frondosa</i>	1.0	0.25	0.25	0	>1.0 ^I
<i>H. erinaceus</i>	1.0	0.25	0.02	12.5	0.33 ^S
<i>H. tessulatus</i>	1.0	0.25	0.03	8.3	0.37 ^S
<i>L. edodes</i>	1.0	0.25	0.25	0	>1.0 ^I
<i>P. adiposa</i>	1.0	0.25	0.01	25.0	0.29 ^S
<i>P. citrinopileatus</i>	0.25	0.25	0.25	0	>1.0 ^I
<i>P. eryngii</i>	1.0	0.25	0.07	3.6	0.53 ^A
<i>P. microspora</i>	0.25	0.25	0.25	0	>1.0 ^I
<i>P. ostreatus</i>	1.0	0.25	0.25	0	>1.0 ^I
<u>Amoxicillin</u>					
<i>A. bisporus</i>	1.0	0.25	0.01	25.0	0.29 ^S
<i>G. frondosa</i>	1.0	0.25	0.25	0	>1.0 ^I
<i>H. erinaceus</i>	1.0	0.25	0.03	8.3	0.37 ^S
<i>H. tessulatus</i>	1.0	0.25	0.04	6.3	0.41 ^S
<i>L. edodes</i>	1.0	0.25	0.25	0	>1.0 ^I
<i>P. adiposa</i>	1.0	0.25	0.02	12.5	0.33 ^S
<i>P. citrinopileatus</i>	0.25	0.25	0.25	0	>1.0 ^I
<i>P. eryngii</i>	1.0	0.25	0.06	4.2	0.49 ^S
<i>P. microspora</i>	0.25	0.25	0.25	0	>1.0 ^I
<i>P. ostreatus</i>	1.0	0.25	0.25	0	>1.0 ^I
<u>Oxacillin</u>					
<i>A. bisporus</i>	1.0	0.0625	0.0625	0	>1.0 ^I
<i>G. frondosa</i>	1.0	0.0625	0.0625	0	>1.0 ^I

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

<i>H. erinaceus</i>	1.0	0.0625	0.0625	0	>1.0 ^I
<i>H. tessulatus</i>	1.0	0.0625	0.0625	0	>1.0 ^I
<i>L. edodes</i>	1.0	0.0625	0.0625	0	>1.0 ^I
<i>P. adiposa</i>	1.0	0.0625	0.0625	0	>1.0 ^I
<i>P. citrinopileatus</i>	0.25	0.0625	0.0625	0	>1.0 ^I
<i>P. eryngii</i>	1.0	0.0625	0.0625	0	>1.0 ^I
<i>P. microspora</i>	0.25	0.0625	0.0625	0	>1.0 ^I
<i>P. ostreatus</i>	1.0	0.0625	0.0625	0	>1.0 ^I
				<u>Penicillin</u>	
<i>A. bisporus</i>	1.0	0.25	0.01	25.0	0.29 ^S
<i>G. frondosa</i>	1.0	0.25	0.25	0	>1.0 ^I
<i>H. erinaceus</i>	1.0	0.25	0.025	10.0	0.35 ^S
<i>H. tessulatus</i>	1.0	0.25	0.06	4.2	0.49 ^S
<i>L. edodes</i>	1.0	0.25	0.25	0	>1.0 ^I
<i>P. adiposa</i>	1.0	0.25	0.025	10.0	0.35 ^S
<i>P. citrinopileatus</i>	0.25	0.25	0.25	0	>1.0 ^I
<i>P. eryngii</i>	1.0	0.25	0.07	3.6	0.53 ^A
<i>P. microspora</i>	0.25	0.25	0.25	0	>1.0 ^I
<i>P. ostreatus</i>	1.0	0.25	0.25	0	>1.0 ^I

Modulating activity is classified into synergism (<0.5 (s)), additive (0.5-1 (a)), indifference (>1-4 (I)), and antagonism (>4 (ANT)), with reference to the FIC index; N=3

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.

Table 3. Extracted yields for each respective edible mushroom species, expressed as a % from starting dry mass (20 g). Ethyl acetate and aqueous methanol extracts were derived from partitioning the methanol extract*

Species	<u>Y(extract)/%</u>				
	Hexane	Methanol	Water	Ethyl acetate*	Aqueous methanol*
<i>A. bisporus</i>	0.9	18.6	62.0	0.48	15.1
<i>G. frondosa</i>	1.3	19.9	71.3	0.31	14.4
<i>H. erinaceus</i>	1.8	32.2	54.0	0.45	20.2
<i>H. tessellatus</i>	2.8	17.5	49.6	1.09	12.7
<i>L. edodes</i>	0.9	23.7	62.1	0.5	20
<i>P. adiposa</i>	1.8	25.2	61.5	0.37	17.6
<i>P. microspora</i>	1.2	22.9	65.9	0.56	17.4
<i>P. citrinopileatus</i>	1.1	23.9	59.8	0.77	16.3
<i>P. eryngii</i>	0.9	31.7	55.5	0.26	24.5
<i>P. ostreatus</i>	1.5	22.3	67.3	0.35	17.6

Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.




Fig. 1. Cell viability assay of sub-inhibitory concentrations of *A. bisporus* ethyl acetate extract and ampicillin, and the subsequent antibiotic-modulating effects when combined. DAPI region indicates live cells, while PI indicates membrane-compromised cells. Daptomycin was used as a positive control, while 0.1 % (V/V) DMSO was used as a negative control ($N=3$)